Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teriflunomide - Sanofi Genzyme

Drug Profile

Teriflunomide - Sanofi Genzyme

Alternative Names: A-77-1726; Aubagio; AVE-1726; HMR-1726; HMR1726D; RS-61980; SU-0020

Latest Information Update: 01 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Genzyme Corporation; Sanofi; Sanofi Genzyme
  • Class Anti-inflammatories; Antirheumatics; Hydroxybutyrates; Nitriles; Small molecules; Toluidines
  • Mechanism of Action Cytochrome P 450 cyp2c8 inhibitors; Dihydroorotate dehydrogenase inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Research Neurological disorders

Most Recent Events

  • 22 Jul 2019 Teriflunomide is not yet available for Multiple sclerosis (Monotherapy) in Argentina, Chile, Colombia, Dominican Republic, Guatemala, Honduras, Mexico, New Zealand, Panama, Peru, Russia, South Korea, Ukraine (PO)
  • 04 May 2019 Pharmacodynamics data from a early research in Neurological disorders presented at the 71th Annual Meeting of the American Academy of Neurology (AAN-2019)
  • 04 Mar 2019 Sanofi plans a phase IV trial for relapsing forms of Multiple sclerosis in March 2019 (PO) (NCT03856619)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top